

Antisense Research and Application

Contributors

S. Agrawal, T. Akiyama, C.F. Bennett, M. Butler,
B.J. Chiasson, T.P. Condon, P.D. Cook, S.J. Craig,
R.M. Crooke, S.T. Crooke, G. Davidkova, N.M. Dean,
F.A. Dorr, D. Fabbro, R.S. Geary, T. Geiger, A.M. Gewirtz,
M.O. Hebb, S.P. Henry, M. Hogan, S.L. Hutcherson,
F. Kalkbrenner, D.L. Kisner, A.M. Krieg, J.M. Leeds,
A.A. Levin, R.R. Martin, B.P. Monia, D.K. Monteith,
M. Müller, P.L. Nicklin, P.E. Nielsen, J.A. Phillips,
H.A. Robertson, P.J. Schechter, G. Schultz, W.R. Shanahan,
Jr., M.V. Templin, B. Weiss, B. Wittig, R. Zhang

Editor

Stanley T. Crooke



Springer

Contents

CHAPTER 1

Basic Principles of Antisense Therapeutics

S.T. CROOKE. With 3 Figures	1
A. Introduction	1
B. Proof of Mechanism	1
I. Factors that May Influence Experimental Interpretations	1
1. Oligonucleotide Purity	1
2. Oligonucleotide Structure	2
3. RNA Structure	2
4. Variations in In Vitro Cellular Uptake and Distribution	2
5. The Binding to and Effects of Binding to Nonnucleic Acid Targets	3
6. Terminating Mechanisms	3
7. Effects of "Control Oligonucleotides"	4
8. Kinetics of Effects	4
II. Recommendations	4
1. Positive Demonstration of Antisense Mechanism and Specificity	4
C. Molecular Mechanisms of Antisense Drugs	5
I. Occupancy Only Mediated Mechanisms	5
1. Inhibition of Splicing	5
2. Translational Arrest	6
3. Disruption of Necessary RNA Structure	7
II. Occupancy Activated Destabilization	8
1. 5' Capping	8
2. Inhibition of 3' Polyadenylation	9
III. Other Mechanisms	9
IV. Activation of RNase H	10
V. Activation of Double-Strand RNase	12
D. Characteristics of Phosphorothioate Oligodeoxynucleotides ...	12
I. Introduction	12
II. Hybridization	13

III. Interactions with Proteins	13
IV. Pharmacokinetic Properties	15
1. Nuclease Stability	15
2. In Vitro Cellular Uptake	16
3. In Vivo Pharmacokinetics	16
V. Pharmacological Properties	20
1. Molecular Pharmacology	20
2. In Vivo Pharmacological Activities	22
VI. Toxicological Properties	26
1. In Vitro	26
2. Genotoxicity	27
3. In Vivo	28
VII. Therapeutic Index	29
VIII. Conclusions	30
E. The Medicinal Chemistry of Oligonucleotides	31
I. Introduction	31
II. Heterocycle Modifications	32
1. Pyrimidine Modifications	32
2. Purine Modifications	33
3. Oligonucleotide Conjugates	33
a) Nuclease Stability	34
b) Enhanced Cellular Uptake	34
c) RNA Cleaving Groups	35
d) In Vivo Effects	35
4. Sugar Modifications	36
5. Backbone Modifications	37
III. Conclusions	38
References	38

CHAPTER 2

Antisense Medicinal Chemistry

D. Cook. With 11 Figures	51
A. Introduction	51
B. Scope of the Review	51
C. Phosphorothioates as Antisense Drug Candidates	52
D. Phosphorothioate Limitations	53
I. Pharmacodynamic Limitations	53
II. Pharmacokinetic Limitations	54
III. Toxicological Limitations	54
E. Types of Oligonucleotide Modifications	55
F. Drug Properties of Antisense Oligonucleotides that May Be Altered by Chemical Modifications	55

G. Why Is it Important to Continue to Design and Synthesize Antisense Oligonucleotides with Increased Affinity for Target RNA and with Greater Resistance to Nucleolytic Degradation?	56
H. What Are the Standards for Binding Affinity, Nuclease Resistance, and Other Properties Recently Achieved by Structure–Property/Activity Relationship Studies of Oligonucleotides?	57
I. Summary of Key Oligonucleotide Modifications	59
I. Heterocycles (Nucleobases)	59
1. 5'-Position Pyrimidine- and Tricyclic Cytidine-Modified Oligonucleotides	59
2. N ² -Purine-Modified Oligonucleotides	61
3. 7-Deaza-Modified Oligonucleotides	63
4. Additional Advantages of Heterocycle-Modified Oligonucleotides	64
5. Toxicity Liability of Heterocyclic Modifications	65
II. Carbohydrate-Modified Oligonucleotides	66
1. Basis for Design	67
2. 4'-Modified Oligonucleotides	67
3. Sugar Conformationally Restricted Oligonucleotides	67
4. Morpholino Diamidate-Modified Oligomers	69
5. 2'-Modified Oligonucleotides	69
a) Structure–Property/Activity Relationship Studies	69
α) Binding Properties of 2'-O-Modified Oligonucleotides	70
β) Stability of 2'-O-Modified Oligonucleotides	71
b) Modes of Action of 2'-Modified Oligonucleotides	72
α) Chimera 2'-O-Modified Oligonucleotides – RNase H-Dependent Mode of Action (Gapmer Technology)	72
β) 2'-O-Modified Oligonucleotides with an RNase H-Independent Mode of Action	76
c) Selected, Interesting Antisense Results With 2'-O-Modified Oligonucleotides in Gapmer Motifs	77
d) Pharmacokinetic Properties of 2'-Modified Oligonucleotides	78
e) Toxicity Implications of 2'-Modified Oligonucleotides	80
f) Summary of 2'-Sugar Modified Oligonucleotides	81

III. Backbone- or Linkage-Modified Oligonucleotides	82
1. MMI- and Amide-3-Modified Oligonucleosides/tides	82
2. 3'-Amidate-Modified Oligonucleotides	84
3. 3'-Thioformacetal- and Formacetal-Modified Oligomers	85
4. 2'-Modified <i>Rp</i> -Me-Phosphonates	85
5. Peptide Nucleic Acid	85
6. General Observations About Backbone Research	86
IV. Oligonucleotide Pendants (Conjugates)	87
J. Conclusions	90
References	92

CHAPTER 3

In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides

R.M. CROOKE. With 14 Figures	103
A. Introduction	103
B. Stability in the Extracellular Milieu	104
I. Phosphodiester Oligonucleotides	104
II. Methylphosphonate Oligonucleotides	105
III. Phosphorothioate Oligonucleotides	106
C. In Vitro Uptake, Intracellular Distribution, and Efflux	106
I. Phosphodiester Oligonucleotides	106
1. Uptake	106
2. Intracellular Distribution	109
3. Efflux	110
II. Methylphosphonate Oligonucleotides	111
1. Uptake	111
2. Intracellular Distribution	112
3. Efflux	112
III. Phosphorothioate Oligonucleotides	113
1. Uptake	113
2. Intracellular Distribution	116
3. Efflux	119
D. Intracellular Stability	120
I. Phosphodiester Oligonucleotides	101
II. Methylphosphonate Oligonucleotides	122
III. Phosphorothioate Oligonucleotides	122
E. Uptake Enhancement Methods	128
F. Conclusions	130
References	133

CHAPTER 4

**Pharmacokinetic Properties of Phosphorothioates in Animals –
Absorption, Distribution, Metabolism and Elimination**

P.L. NICKLIN, S.J. CRAIG, and J.A. PHILLIPS. With 12 Figures	141
A. Introduction	141
I. Phosphorothioate Modification	143
II. Oligonucleotide Detection and Analysis	144
B. Distribution	145
I. Blood Kinetics	145
II. Tissue Distribution	147
III. Cellular Uptake In Vivo	147
IV. Dose Dependence	150
V. Sequence Dependence	150
VI. Multiple Dosing	153
C. Metabolism	153
I. Plasma	155
II. Tissues	155
D. Elimination	159
E. Absorption	161
I. Parenteral Administration	162
II. Local Administration	164
III. Non-parenteral Administration	164
F. Conclusion	165
References	166

CHAPTER 5

Toxicity of Oligodeoxynucleotide Therapeutic Agents

A.A. LEVIN, D.K. MONTEITH, J.M. LEEDS, P.L. NICKLIN, R.S. GEARY, M. BUTLER, M.V. TEMPLIN, and S.P. HENRY. With 13 Figures	169
A. Introduction	169
B. Pharmacokinetics and Metabolism	173
C. Toxicity of Phosphorothioate Oligodeoxynucleotides	179
I. Genetic Toxicity	179
II. Acute Toxicities	179
1. Complement Activation	180
a) Effects of Oligodeoxynucleotide Chemistries	186
2. Hemostasis	187
a) Effects of Oligodeoxynucleotide Chemistries	191
III. Toxicologic Effects Associated with Chronic Exposure	192
1. Immune Stimulation	192
a) Effects of Oligodeoxynucleotide Chemistries	199

2. Hepatic Effects of Oligodeoxynucleotide Treatment	200
3. Renal Effects of Oligodeoxynucleotide Treatment ...	202
4. Hematopoiesis	205
IV. Reproductive Effects of Antisense Oligodeoxynucleotides	205
V. Ocular Toxicity of Antisense Therapeutic Agents	206
1. Ocular Pharmacokinetics	207
2. Ocular Toxicity Profile	208
References	210

CHAPTER 6

Pharmacokinetic Properties of Phosphorothioate Oligonucleotides in Humans

J.M. LEEDS and R.S. GEARY. With 4 Figures	217
A. Introduction	217
B. Human Pharmacokinetics	218
I. Absorption	219
II. Plasma Pharmacokinetics	220
1. Peak Plasma Concentrations	220
2. Calculated Parameters	221
III. Metabolism	223
IV. Elimination	228
C. Pharmacodynamics	230
References	231

CHAPTER 7

Safety and Tolerance of Phosphorothioates in Humans

P.J. SCHECHTER and R.R. MARTIN. With 3 Figures	233
A. Introduction	233
B. Cardiovascular Safety	233
C. Hematological Safety	234
I. Coagulation	234
II. Platelets	235
III. Red Blood Cells	236
D. Complement Activation	237
E. Specific Organ Toxicity	237
F. Conclusion	239
References	239

CHAPTER 8

Immune Stimulation by Oligonucleotides

A.M. KRIEG	243
------------------	-----

A. Sequence-Independent Immune Effects of the DNA Backbone	243
B. Sequence-Specific Immune Effects of CpG Motifs in Oligodeoxynucleotides	245
I. Immune Activation by Bacterial DNA and the Identification of Stimulatory Palindromes	245
II. Immune Activation by Antisense and Control Oligodeoxynucleotides	246
III. Discovery of Immune Activation by CpG Motifs	247
IV. Immune Effects of CpG Motifs	250
1. Mitogenic and Anti-apoptotic Effects of Oligodeoxynucleotides	250
a) Virtually All B Cells Can Respond to the Mitogenic Effects of CpG Oligodeoxynucleotides	250
b) CpG DNA Blocks B Cell Apoptosis	251
c) Induction of B Cell Cytokine and Ig Secretion by CpG DNA	251
2. Induction of Monocyte Cytokine Secretion by CpG DNA	252
3. Induction of Natural Killer Interferon- γ Secretion and Lytic Activity by CpG DNA	253
V. Role of the Phosphorothioate Backbone in the Immune Effects of CpG Oligodeoxynucleotides	254
VI. Mechanism of Leukocyte Activation by CpG Oligodeoxynucleotides	254
VII. Teleologic Significance of Immune Activation by CpG Motifs in DNA	256
C. Sequence-Specific Immune Effects of Poly(G) Motifs in Oligodeoxynucleotides	258
References	258

CHAPTER 9

Pharmacological Inhibition of Dopaminergic and Other Neurotransmitter Receptors Using Antisense Oligodeoxynucleotides

G. DAVIDKOVA and B. WEISS. With 5 Figures	263
A. Introduction	263
B. Advantages of Antisense Oligodeoxynucleotides over Traditional Pharmacological Antagonists	264
C. Factors to Consider in the Development of Antisense Oligodeoxynucleotides Targeted to Neurotransmitter Receptors	266
I. Structure of Antisense Oligodeoxynucleotides: Optimal Recognition Site on the Targeted Transcript and	

Oligodeoxynucleotide Length and Chemical Structure	266
II. In Vitro and In Vivo Substrates for Studying Antisense Oligodeoxynucleotides	272
III. Delivery Systems	273
D. Uptake and Distribution of Antisense Oligodeoxynucleotides	273
E. Mechanism of Action of Antisense Oligodeoxynucleotides	276
I. Mechanisms of Inhibition of Gene Expression	276
II. Appropriate Controls to Determine the Specificity of Antisense Effects	277
III. Functional, Biochemical, and Molecular Consequences of Antisense Inhibition	277
IV. Antisense Oligodeoxynucleotides Inhibit a Pool of Functional Neurotransmitter Receptors	278
F. In Vitro and In Vivo Effects of Antisense Oligodeoxynucleotides Targeted to the Transcripts Encoding Neurotransmitter Receptors	281
I. Acetylcholine Receptors	281
II. Adrenergic Receptors	282
III. Dopamine Receptors	283
1. In Vivo Models for Studying the Effects of Dopamine Receptor Antisense Oligodeoxynucleotides	285
2. Design and Synthesis of Antisense Oligodeoxynucleotides Targeted to the Dopamine Receptor Intended for In Vivo Use	286
3. D ₁ Dopamine Receptor Antisense	286
a) In Vivo Studies	286
b) In Vitro Studies	289
4. D ₂ Dopamine Receptor Antisense	290
a) In Vivo Studies	290
b) In Vitro Studies	293
5. D ₃ Dopamine Receptor Antisense	294
IV. GABA Receptors	295
V. NMDA Receptors	298
VI. Serotonin Receptors	299
G. Future Directions: Comparison Between the Properties of Antisense Oligodeoxynucleotides and Antisense RNA Produced by Mammalian Expression Vectors	300
H. Conclusions	301
References	302

CHAPTER 10

Pharmacological Effects of Antisense Oligonucleotide Inhibition of Immediate-Early Response Genes in the CNS

B.J. CHIASSON, M.O. HEBB, and H.A. ROBERTSON. With 3 Figures 309

A. Introduction	309
B. Some Correlative Studies Suggesting a Role of Immediate-Early Genes in Brain Function	309
C. Immediate-Early Genes and Stimulus-Transcription Coupling	311
I. A Model for Change	311
II. The Origin of Immediate-Early Genes	312
III. The Immediate-Early Gene as an Inducible Transcription Factor	312
IV. Immediate-Early Gene Transcription Factors and Their Targets	313
D. Studies Using Antisense Oligodeoxynucleotides in the CNS ...	315
I. The Induction of <i>c-fos</i> in the Striatum	315
II. Knockdown of Amphetamine-Induced <i>c-fos</i> Using Antisense Oligodeoxynucleotides: Studies of the Basal Ganglia Function	317
III. The Amygdala and Gene Expression	322
IV. Exploring Alternative Modifications to Oligonucleotides	328
V. Reconciling Differences	330
VI. Other Studies Using Antisense Oligonucleotides in Nervous Tissue	331
E. Neural Plasticity and the Role of <i>c-fos</i> as Demonstrated by Antisense Technology	332
References	333

CHAPTER 11

Inhibition of G Proteins by Antisense Drugs

F. KALKBRENNER, B. WITTIG, and G. SCHULTZ. With 4 Figures	341
A. Introduction	341
B. Antisense Approaches to Study Signal Transduction Pathways	344
C. Inhibition of G-Protein Functions by Antisense RNA and Genomic Knockout	345
D. Inhibition of G-Protein Functions by Antisense Oligodeoxynucleotides in Cell Culture	350
I. Nuclear Microinjection of G-Protein Antisense Oligodeoxynucleotides	350
II. Signal Transduction Pathways Leading to G-Protein-Mediated Inhibition of Voltage-Gated Calcium Channels in Neuroendocrine Cells	352
III. Signal Transduction Pathways Leading to a G-Protein-Mediated Increase in the Intracellular Calcium Concentration	354

IV. Specificity of Antisense Effects	356
V. Application of G-Protein Antisense Oligodeoxynucleotides Through the Patch- Clamp Pipette	357
VI. Application of G-Protein Antisense Oligodeoxynucleotides by Adding to the Cell Culture Medium	358
E. Inhibition of G-Protein Functions by Antisense Oligodeoxynucleotides in Animals	360
F. Perspectives	363
References	364

CHAPTER 12

Use of Antisense Oligonucleotides to Modify Inflammatory Processes

C.F. BENNETT and T.P. CONDON. With 1 Figure	371
A. Introduction	371
B. Cell Adhesion Molecules	373
I. Intercellular Adhesion Molecule 1	376
1. Pharmacology of ICAM-1 Antisense Oligonucleotides	377
a) Proof of Mechanism	377
b) Human Xenografts	378
c) Rodent Allografts	379
d) Colitis	381
e) Renal Ischemia	382
2. Toxicology of ICAM-1 Antisense Oligonucleotides ...	382
3. Clinical Studies with ISIS 2302	383
4. Second and Third Generation Chemistry	383
II. Other Endothelial Cell-Leukocyte Adhesion Molecules	384
C. Nuclear Factor- κ B	385
D. Interleukin-1 Receptors	386
E. Conclusions	386
References	387

CHAPTER 13

Antisense Oligonucleotides and Their Anticancer Activities

D. FABBRO, M. MÜLLER, and T. GEIGER. With 6 Figures	395
A. Potential Cancer Targets for Pharmaceutical Intervention	395
B. Antisense-Based Approaches and Cancer	396
C. Antisense Targets Related to Solid Tumors	396
I. <i>ras</i> and <i>raf</i>	396

II. Growth Factors and Growth Factor Receptors	404
III. Proteases	405
IV. Multidrug Resistance	405
V. Miscellaneous	406
D. Antisense Targets Related to Hematological Malignancies	407
I. Chronic Myelogenous Leukemia and <i>bcr-abl</i>	407
II. <i>myc</i> , <i>myb</i> , and <i>bcl-2</i>	408
E. Protein Kinase C- α and <i>raf</i> as Cancer Targets for Antisense ...	408
I. In Vivo Activity of Phosphorothioate Antisense Oligonucleotide Targeting Protein Kinase C- α and <i>c-raf</i>	408
II. In Vivo Activity of Modified and Formulated Antisense Oligonucleotides Targeting <i>c-raf</i>	410
1. 2'-Methoxy-ethoxy-Modified Oligonucleotides	410
2. Antitumor Activity of CGP 69846A in Stealth Liposomes	411
3. Antitumor Activity of CGP 69846A with Dextran Sulfate or as Cholesterol Conjugates of CGP 69846A	411
F. Concluding Remarks	414
References	417

CHAPTER 14

Pharmacological Activity of Antisense Oligonucleotides in Animal Models of Disease

B.P. MONIA and N.M. DEAN	427
A. Introduction	427
B. Vascular System	427
I. Restenosis	427
II. Atherosclerosis	432
III. Hypertension	434
IV. Ocular Neovascularization	435
C. Skin	436
D. Peripheral Organs	437
I. Liver	438
II. Kidney	439
III. Lung	439
E. Conclusions and Future Directions	440
References	440

CHAPTER 15

Clinical Antiviral Activities

S.L. HUTCHERSON. With 2 Figures	445
---------------------------------------	-----

A. Introduction	445
B. Antisense Oligonucleotide Antiviral Pharmacology	447
C. Pharmacokinetic Assessment Strategies	448
D. Toxicology for Antisense Oligonucleotide Antivirals	449
E. Chemical Synthesis Scale-Up and Chemical Development	450
F. Clinical Research of Antisense Oligonucleotides	450
G. Future Antisense Antiviral Development	455
References	456

CHAPTER 16

Antisense Oligonucleotides to Protein Kinase C- α and C-*raf* Kinase: Rationale and Clinical Experience in Patients with Solid Tumors

F.A. DORR and D.L. KISNER	463
A. Introduction	463
B. Rationale for the Development of an Inhibitor of Protein Kinase C (ISIS 3521)	464
C. Rationale for the Development of an Inhibitor of C- <i>raf</i> Kinase (ISIS 5132)	465
D. Preclinical Toxicology and Pharmacokinetics	466
E. Status of Clinical Development	468
I. ISIS 3521	468
1. Clinical Study 1	468
2. Clinical Study 2	469
II. ISIS 5132	471
1. Clinical Study 1	471
2. Clinical Study 2	472
F. Future Clinical Development	473
References	474

CHAPTER 17

Nucleic Acid Therapeutics for Human Leukemia: Development and Early Clinical Experience with Oligodeoxynucleotides Directed at c-*myb*

A.M. GEWIRTZ. With 10 Figures	477
A. Introduction	477
B. c- <i>myb</i> Proto-oncogene	477
I. Targeting the c- <i>myb</i> Gene	479
II. In Vitro Experience in the Hematopoietic Cell System	479
1. Role of c- <i>myb</i> -Encoded Protein in Normal Human Hematopoiesis	479

2. Myb Protein Requirement for Leukemic Hematopoiesis	480
3. Differential Reliance of Normal and Leukemic Progenitor Cells on <i>c-myb</i> Function	483
4. Use of <i>c-myb</i> Oligodeoxynucleotides as Bone Marrow-Purging Agents	484
5. Efficacy of <i>c-myb</i> Oligodeoxynucleotides In Vivo: Development of Animal Models	485
III. Why Downregulating <i>myb</i> Kills Leukemic Cells Preferentially: A Hypothesis	487
IV. Pharmacodynamic Studies with an <i>myb</i> -Targeted Oligodeoxynucleotide	488
C. Use of Antisense Oligonucleotides in a Clinical Setting	491
D. Future Outlook	492
E. Conclusions	494
References	495

CHAPTER 18

Properties of ISIS 2302, an Inhibitor of Intercellular Adhesion Molecule-1, Humans

W.R. SHANAHAN JR. With 8 Figures	499
A. Introduction	499
B. Phase I Intravenous Trial	501
I. Methods and Material	501
II. Results	502
1. Safety	502
2. Pharmacokinetics	504
III. Discussion	510
C. Phase IIa Trials	513
I. Crohn's Disease	514
II. Rheumatoid Arthritis	517
III. Ulcerative Colitis	517
IV. Psoriasis	517
V. Renal Transplantation	518
D. Exploration of Subcutaneous Dosing	519
E. Future Plans	523
References	521

CHAPTER 19

Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals

S. AGRAWAL and R. ZHANG. With 10 Figures	525
--	-----

A. Introduction	525
B. Oral Administration	526
I. Experimental Design	526
1. Synthesis of Unlabeled and [³⁵ S]-Labeled Oligonucleotides	526
2. Animals and Drug Administration	526
3. Absolute Bioavailability	527
4. Sample Preparation and Total Radioactivity Measurements	528
5. Gel Electrophoresis	528
6. High-Performance Liquid Chromatography Analysis	528
II. Results and Discussion	529
1. Phosphorothioate Oligonucleotide	529
2. Mixed-Backbone Oligonucleotide-1	529
3. Mixed-Backbone Oligonucleotide-2	532
4. General Discussion	533
C. Colorectal Administration	534
I. Special Considerations in Experimental Design	534
II. Results and Discussion	535
1. Mixed-Backbone Oligonucleotide-1	535
2. Phosphorothioate Oligonucleotide and End-Modified Mixed-Backbone Oligonucleotide-2	536
3. General Discussion	538
D. Conclusions	540
References	541

CHAPTER 20

Antisense Properties of Peptide Nucleic Acid

P.E. NIELSEN. With 7 Figures	545
A. Introduction	545
B. Chemistry	545
C. Hybridization Properties	545
D. Structure of Peptide Nucleic Acid Complexes	547
E. Antisense Activity (Mechanism of Action)	548
F. Cellular Biology	549
G. Peptide Nucleic Acid Derivatives (Structure–Activity Relationships)	549
H. Peptide Nucleic Acid–DNA Chimeras	553
I. Antigene Activity	555
J. Future Prospects	557
References	557

CHAPTER 21

Triple Helix Strategies and Progress

T. AKIYAMA and M. HOGAN. With 2 Figures	561
A. Introduction	561
B. Discovery of the Triple Helix Structure	561
C. Detailed Structure of the Triple Helix	562
I. Nuclear Magnetic Resonance Studies	564
1. Hydrogen Bonding	564
2. Base Orientation	564
II. Other Methods to Investigate Triple Helix Structure ...	565
1. Infrared Spectroscopy	565
2. Phase-Sensitive Electrophoresis	565
3. Electron Microscopy	565
4. X-ray Crystallography	566
5. Molecular Dynamics Simulation	566
D. Stability of the Triple Helix	566
I. Thermodynamic Analysis by Spectroscopic and Calorimetric Methods	566
II. Thermodynamic Analysis by Biochemical Methods	568
III. Factors Influencing the Stability of the Triple Helix	569
1. Mismatching at Inversion Sites	569
2. Ionic Strength	570
3. Effect of pH	571
IV. Kinetics of Triple Helix Formation	571
E. Nucleoside Modification to Improve Triple Helix Stability	571
I. Modified Nucleoside to Overcome pH Dependency of the Parallel Triple Helix	571
1. Cytidine Derivatives	572
2. Adenosine Derivatives	572
3. Guanosine Derivatives	573
II. New Nucleosides to Recognize Inversion Sites	573
III. Modification to Overcome Alkali Metal Mediated Inhibition of Antiparallel Triple Helix Formation	573
F. Triple Helix Binding Ligands	574
I. The Triple Helix as a Target for Small Molecule Recognition	574
II. Ethidium Bromide	574
III. Benzopyridoindole Derivatives	575
IV. Naphthyl-Quinoline Derivative	575
V. Other Intercalators	575
VI. Minor Groove Binding Ligands	576
VII. Polyamines and Basic Oligopeptides	576
G. Backbone Modification and Strand Switching	577
I. DNA and RNA Backbone	577

II. Chemical Modification of Backbones	577
III. Alternate Strand Recognition and Minor Helix Groove Bridging	578
H. Conjugation of Small Compounds Enhance Triple Helix Stability	579
I. Conjugation of Intercalators	579
II. Conjugation of Other Small Compounds	580
I. Inhibition of Transcription by Triple Helix Technology	580
I. Prospects for Triple Helix Mediated Gene Regulation	580
II. Inhibition of Transcription Factor Binding by Triple Helix Formation	581
III. Inhibition of Transcription by Triple Helix Formation in a Cell-free System	581
IV. Change of Nucleosome Positioning by Triple Helix Formation	584
V. Transcription Inhibition by Triple Helix Formation in Cell	584
J. Other Pharmaceutically Interesting Effects of Triple Helix Formation	587
I. Inhibition of DNA Replication	587
II. Inhibition of HIV Integration by Triple Helix	587
K. Targeting Single-Stranded DNA or RNA by Triple Helix Formation	588
L. DNA Modification Mediated by TFO Binding	589
I. Sequence-Specific DNA Cleavage	589
II. Sequence-Specific Alkylation	589
III. Single-Site Enzymatic Cleavage	589
IV. Photo-Induced Cross-Linking	590
V. Targeted Mutagenesis by a Psoralen-Linked TFO	590
M. Recent Topics and Prospects	591
I. Artificial DNA Bending by Triple Helix Formation	591
N. Conclusion	592
References	593
Subject Index	611